Comparative Pharmacology
Head-to-head clinical analysis: OMNIPAQUE 12 versus OSMOVIST 240.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPAQUE 12 versus OSMOVIST 240.
OMNIPAQUE 12 vs OSMOVIST 240
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopaque agent that attenuates X-rays, providing contrast in imaging. Iodine atoms absorb X-rays, enhancing visualization of blood vessels and tissues.
Nonionic iodinated contrast medium that attenuates X-rays is excreted unchanged in urine; increases density of blood vessels and tissues to enhance radiological visualization.
Adult dose: 12 g iodine (e.g., 200 mL of Omnipaque 12) administered intravenously, intra-arterially, or into body cavities. Typical contrast study dose: 1-2 mL/kg (max 150 mL) for CT; 40-60 mL for angiographic procedures.
Intravenous bolus injection: 0.5 mL/kg to 1 mL/kg of Osnovist 240 (240 mg iodine/mL) for CT enhancement, up to a maximum of 150 mL per dose.
None Documented
None Documented
1-2 hours (normal renal function); prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life approximately 2 hours (range 1.5–4 hours) in patients with normal renal function; prolonged in renal impairment proportional to creatinine clearance.
Renal: >95% unchanged; biliary/fecal: <5%
Primarily renal (glomerular filtration); >95% of administered dose excreted unchanged in urine within 24 hours. Negligible biliary/fecal elimination (<5%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent